doi: 10.1002/hup.1005CrossRefGoogle ScholarPubMed Gong, Y., Chai, Y., Ding, J.-H., Sun, X.-L., & Hu, G
You are literally creating the exact type of damage that BPC-157 is being investigated to prevent or heal
doi: 10.3389/fphar.2022.1016639 61 Tirzepatide
In contrast to self-reported surveys, passive observation has higher accuracy in areas where self-reporting doesnt, such as recall area and social desirability bias 30

Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects